



# 2024 ACCP Annual Meeting

*"Transformative Solutions: Delivering on the Promise of Clinical Pharmacology for Patient Care"*

September 8 – 10, 2024 • N Bethesda, MD

## 2024 ACCP Distinguished Investigator Award

### **Raman Venkataramanan, PhD, FCP, FAAPS**

Distinguished Service Professor, Director of Clinical Pharmacokinetics Lab, Director of TDM & Toxicology, UPMC, Dept of Pharmaceutical Sciences & Pathology  
STI, MIRM, MWRI, UPCI Univ of Pittsburgh

Dr. Raman Venkataramanan is an expert in basic and clinical pharmacology. His work has been supported by more than 220 research grants (as PI or Co-PI or co-investigator) and he has conducted research that directly benefits the clinical care and quality of life of numerous patients, especially those who are pregnant or those who undergo various organ transplantations. Over the course of his 43 years of academic career, Dr. Venkataramanan has made significant contributions to the understanding of clinical pharmacology and optimizing the dosing regimen of six drugs in transplantation (212 peer reviewed publications) and in pregnancy (61 peer reviewed publications) as well as played a key role in the initial evaluation of the Univ of Wisconsin (UW) solution for preservation of organs at the Univ of Pittsburgh Medical Ctr (UPMC). He currently serves as the director of the TDM and Toxicology service in UPMC.

At the Univ of Pittsburgh, he has led the preclinical evaluation and coordinated the clinical studies of FK506 (tacrolimus) in transplant patients. These studies were instrumental in advancing the status of FK506 as the primary immunosuppressive drug that is currently used in > 90% of the transplant patients all over the world. His work has also evaluated the clinical pharmacology of cyclosporine and paved the way for personalizing the dose of cyclosporine and FK506 through therapeutic drug monitoring. His work has evaluated the functional capacity of the transplanted organs. His work has identified the need for personalizing the dose of 17-OHP caproate, the only drug that was ever approved by the US FDA for this indication to improve treatment outcomes. He has also performed clinical and computational studies to identify decreased exposure to buprenorphine in pregnancy and to optimize the dose of buprenorphine in pregnant women to improve treatment outcomes.

Dr. Venkataramanan has been recognized for his scientific and clinical contributions by several national and international organizations. He is a Fellow of ACCP and AAPS and a Distinguished Service Professor at the Univ of Pittsburgh. He is passionate about teaching and has mentored > 150 undergraduate students, graduate students, residents and fellows, who hold leadership positions in academia, industry and federal agencies.